Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blind, Placebo-controlled, Dose-ranging Study to Investigate the Effect on Glycemic Control, Safety, Pharmacokinetics and Pharmacodynamics of GLP-1 in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin.
Brief Summary: This 6 arm study will evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of multiple doses and regimens of a GLP-1 analogue in patients with type 2 diabetes who are treated with a stable dose of metformin. Patients will be randomized to receive either subcutaneous placebo, or subcutaneous GLP-1 analogue, 5mg, 10mg or 20mg weekly, or 10mg or 20mg every 2 weeks. All patients will continue on their existing metformin treatment regimen throughout the study. The anticipated time on study treatment is \<3 months, and the target sample size is 100-500 individuals.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Exenatide Once Weekly | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin Glargine | Intervention Type: DRUG; Name: Exenatide Once Weekly; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Insulin Glargine; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: taspoglutide | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: taspoglutide | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: taspoglutide | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: taspoglutide | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: taspoglutide | Arm Label: 6; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: taspoglutide; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: taspoglutide; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: taspoglutide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: taspoglutide; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: taspoglutide; Assigned to Arm(s): 5
C: Arm Label: Sequence 1; Type: EXPERIMENTAL; Interventions: Drug: Exenatide - Exenatide - Placebo | Arm Label: Sequence 2; Type: EXPERIMENTAL; Interventions: Drug: Exenatide - Placebo - Exenatide | Arm Label: Sequence 3; Type: EXPERIMENTAL; Interventions: Drug: Placebo - Exenatide - Exenatide | Intervention Type: DRUG; Name: Exenatide - Exenatide - Placebo; Assigned to Arm(s): Sequence 1 | Intervention Type: DRUG; Name: Exenatide - Placebo - Exenatide; Assigned to Arm(s): Sequence 2 | Intervention Type: DRUG; Name: Placebo - Exenatide - Exenatide; Assigned to Arm(s): Sequence 3
D: Arm Label: Lira placebo/Lira 2.4 mg/Lira 3.0 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Lira 1.2 mg/Lira 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Lira 1.8 mg/Lira 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Lira 2.4 mg/Lira 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Liraglutide 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: placebo | Arm Label: Orlistat; Type: ACTIVE_COMPARATOR; Interventions: Drug: orlistat | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.2 mg/Lira 3.0 mg, Lira 1.8 mg/Lira 3.0 mg, Lira 2.4 mg/Lira 3.0 mg, Liraglutide 3.0 mg | Intervention Type: DRUG; Name: orlistat; Assigned to Arm(s): Orlistat | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Lira placebo/Lira 2.4 mg/Lira 3.0 mg, Liraglutide 3.0 mg

Answer: B